Navigation Links
Hepatitis C Therapy Useless for Some
Date:12/3/2008

Those who don't respond at first not helped by maintenance treatment, study shows

WEDNESDAY, Dec. 3 (HealthDay News) -- Maintenance therapy using low-dose peginterferon doesn't help patients with advanced chronic hepatitis C who haven't responded to an initial round of treatment, new research suggests.

The study also showed a surprising health decline in patients with liver disease over the course of four years.

"This course of treatment had been adopted by a number of doctors in the U.S. and in other countries, though it had yet to be proven to work. That practice should be stopped, based on the results of this trial. There is no rationale for using maintenance therapy. The treatment is clearly ineffective," study author Dr. Adrian Di Bisceglie, chief of hepatology and co-director of the Liver Center at Saint Louis University, said in a university news release.

About half of patients with chronic hepatitis C fully recover after an initial course of peginterferon and ribavirin antiviral therapy that can last from six months to a year. Other patients (non-responders) may show improvement, but the virus isn't eliminated.

The study included 1,050 non-responder patients with advanced liver disease. Half of them received low doses of peginterferon for 3.5 years to try to suppress the hepatitis C virus and slow progression of liver disease. The other patients were assigned to a control group.

After four years, 30 percent of patients in both groups had developed liver failure, liver cancer, or had died. Among those who had milder cirrhosis at the start of the study, 10 percent to 12 percent developed severe liver disease. Both of these findings surprised the researchers.

"Hepatitis patients in these circumstances got very ill over the course of four years, surprisingly so. The lesson we learned is that once chronic hepatitis C gets to the stage of advanced fibrosis, patients can decline rapidly," De Bisceglie said.

The study was published in the Dec. 4 issue of the New England Journal of Medicine.

About 4 million people in the United States are infected with hepatitis C, and 10,000 to 12,000 of them die each year. Hepatitis C is caused by virus that's transmitted through direct contact with an infected person's blood.

More information

The U.S. Centers for Disease Control and Prevention has more about hepatitis C.



-- Robert Preidt



SOURCE: Saint Louis University, news release, Dec. 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hepatitis C Therapy Useless for Some 
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... New York, NY (PRWEB) , ... February 09, 2016 , ... ... announce the appointment of Dr. David Hung to the company´s Board of Directors. ... is a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton ... and Younkers department stores, announced it has raised $176,000 to benefit the Breast ... Comprehensive Cancer Center at the University of Iowa, The Lynn Sage Cancer Research ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER ... ensure lab personnel have a basic understanding of the techniques they use so ... understanding will help them reduce waste and rework to create a leaner overall ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... Feb. 9, 2016 Mast Therapeutics, Inc. ... for sickle cell disease and heart failure, today announced that ... to purchase common stock in an underwritten public offering.  The ... can be no assurance as to whether or when the ... or terms of the offering.   --> ...
Breaking Medicine Technology: